Design Therapeutics (DSGN) Earnings Analysis

Design Therapeutics (DSGN) has no confirmed upcoming earnings date. Last quarter (2026-03-09) it beat with EPS -0.27 USD vs -0.38 USD est (+28.9%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -9.82.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does DSGN next report earnings?

No confirmed upcoming earnings date is currently scheduled for DSGN. This page updates as the calendar is published.

DSGN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-09-0.27 USD-0.38 USD+28.9%Beat
2025-08-07-0.34 USD-0.32 USD-6.3%Miss
2025-03-10-0.24 USD-0.28 USD+14.3%Beat
2024-11-07-0.23 USD-0.26 USD+11.5%Beat
2024-08-05-0.21 USD-0.25 USD+16%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

DSGN valuation and analyst view

Trailing P/E-9.82
Trailing EPS-1.13475 USD
Price / book3.32
Dividend yield0.00%
Market cap0.73B
Analyst consensusBuy (4 buy / 3 hold / 0 sell)
Avg price target20.5 USD

Related research pages

Frequently asked questions

When is Design Therapeutics (DSGN)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for DSGN. This page updates as the calendar is published.

Did DSGN beat earnings last quarter?

In its 2026-03-09 report, DSGN posted EPS of -0.27 USD versus a -0.38 USD estimate — a beat of 28.9%.

What is DSGN's earnings track record?

Over the last 5 reported quarters with consensus data, DSGN beat estimates 4 times (80%).

What is DSGN's current P/E ratio and EPS?

DSGN trades at a trailing P/E of -9.82 on trailing EPS of -1.1347540680631392 USD.

What do analysts rate DSGN?

Analyst consensus is "Buy" across 7 ratings (0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 20.5 USD.